BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23532885)

  • 1. Classifying MMR variants: time for revised nomenclature in Lynch syndrome.
    You YN; Vilar E
    Clin Cancer Res; 2013 May; 19(9):2280-2. PubMed ID: 23532885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis.
    Hinrichsen I; Brieger A; Trojan J; Zeuzem S; Nilbert M; Plotz G
    Clin Cancer Res; 2013 May; 19(9):2432-41. PubMed ID: 23403630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed characterization of MLH1 p.D41H and p.N710D variants coexisting in a Lynch syndrome family with conserved MLH1 expression tumors.
    Pineda M; González-Acosta M; Thompson BA; Sánchez R; Gómez C; Martínez-López J; Perea J; Caldés T; Rodríguez Y; Landolfi S; Balmaña J; Lázaro C; Robles L; Capellá G; Rueda D
    Clin Genet; 2015 Jun; 87(6):543-8. PubMed ID: 25060679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional testing strategy for coding genetic variants of unclear significance in MLH1 in Lynch syndrome diagnosis.
    Hinrichsen I; Schäfer D; Langer D; Köger N; Wittmann M; Aretz S; Steinke V; Holzapfel S; Trojan J; König R; Zeuzem S; Brieger A; Plotz G
    Carcinogenesis; 2015 Feb; 36(2):202-11. PubMed ID: 25477341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).
    Chao EC; Velasquez JL; Witherspoon MS; Rozek LS; Peel D; Ng P; Gruber SB; Watson P; Rennert G; Anton-Culver H; Lynch H; Lipkin SM
    Hum Mutat; 2008 Jun; 29(6):852-60. PubMed ID: 18383312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain.
    Ellison AR; Lofing J; Bitter GA
    Nucleic Acids Res; 2004; 32(18):5321-38. PubMed ID: 15475387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.
    Andersen SD; Liberti SE; Lützen A; Drost M; Bernstein I; Nilbert M; Dominguez M; Nyström M; Hansen TV; Christoffersen JW; Jäger AC; de Wind N; Nielsen FC; Tørring PM; Rasmussen LJ
    Hum Mutat; 2012 Dec; 33(12):1647-55. PubMed ID: 22753075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome patients.
    Zahary MN; Kaur G; Abu Hassan MR; Singh H; Naik VR; Ankathil R
    World J Gastroenterol; 2012 Feb; 18(8):814-20. PubMed ID: 22371642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the effect of unclassified variants identified in MMR genes using phenotypic features, bioinformatics prediction, and RNA assays.
    Pérez-Cabornero L; Infante M; Velasco E; Lastra E; Miner C; Durán M
    J Mol Diagn; 2013 May; 15(3):380-90. PubMed ID: 23523604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of DNA mismatch repair proteins in fresh human blood lymphocytes--towards a novel method for hereditary non-polyposis colorectal cancer (Lynch syndrome) screening.
    Hassen S; Boman BM; Ali N; Parker M; Somerman C; Ali-Khan Catts ZJ; Ali AA; Fields JZ
    J Exp Clin Cancer Res; 2011 Oct; 30(1):100. PubMed ID: 22017758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.